Cargando…

Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes

Mertansine, a tubulin inhibitor, is used as the cytotoxic component of antibody–drug conjugates (ADCs) for cancer therapy. The effects of mertansine on uridine 5′-diphospho-glucuronosyltransferase (UGT) activities in human liver microsomes and its effects on the mRNA expression of cytochrome P450s (...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Won-Gu, Park, Ria, Kim, Dong Kyun, Shin, Yongho, Cho, Yong-Yeon, Lee, Hye Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150891/
https://www.ncbi.nlm.nih.gov/pubmed/32131538
http://dx.doi.org/10.3390/pharmaceutics12030220
_version_ 1783521122787000320
author Choi, Won-Gu
Park, Ria
Kim, Dong Kyun
Shin, Yongho
Cho, Yong-Yeon
Lee, Hye Suk
author_facet Choi, Won-Gu
Park, Ria
Kim, Dong Kyun
Shin, Yongho
Cho, Yong-Yeon
Lee, Hye Suk
author_sort Choi, Won-Gu
collection PubMed
description Mertansine, a tubulin inhibitor, is used as the cytotoxic component of antibody–drug conjugates (ADCs) for cancer therapy. The effects of mertansine on uridine 5′-diphospho-glucuronosyltransferase (UGT) activities in human liver microsomes and its effects on the mRNA expression of cytochrome P450s (CYPs) and UGTs in human hepatocytes were evaluated to assess the potential for drug–drug interactions (DDIs). Mertansine potently inhibited UGT1A1-catalyzed SN-38 glucuronidation, UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-β-glucuronidation, and UGT1A4-catalyzed trifluoperazine N-β-d-glucuronidation, with K(i) values of 13.5 µM, 4.3 µM, and 21.2 µM, respectively, but no inhibition of UGT1A6, UGT1A9, and UGT2B7 enzyme activities was observed in human liver microsomes. A 48 h treatment of mertansine (1.25–2500 nM) in human hepatocytes resulted in the dose-dependent suppression of mRNA levels of CYP1A2, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A9, with IC(50) values of 93.7 ± 109.1, 36.8 ± 18.3, 160.6 ± 167.4, 32.1 ± 14.9, 578.4 ± 452.0, 539.5 ± 233.4, 856.7 ± 781.9, and 54.1 ± 29.1 nM, respectively, and decreased the activities of CYP1A2-mediated phenacetin O-deethylase, CYP2B6-mediated bupropion hydroxylase, and CYP3A4-mediated midazolam 1′-hydroxylase. These in vitro DDI potentials of mertansine with CYP1A2, CYP2B6, CYP2C8/9/19, CYP3A4, UGT1A1, and UGT1A9 substrates suggest that it is necessary to carefully characterize the DDI potentials of ADC candidates with mertansine as a payload in the clinic.
format Online
Article
Text
id pubmed-7150891
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71508912020-04-20 Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes Choi, Won-Gu Park, Ria Kim, Dong Kyun Shin, Yongho Cho, Yong-Yeon Lee, Hye Suk Pharmaceutics Article Mertansine, a tubulin inhibitor, is used as the cytotoxic component of antibody–drug conjugates (ADCs) for cancer therapy. The effects of mertansine on uridine 5′-diphospho-glucuronosyltransferase (UGT) activities in human liver microsomes and its effects on the mRNA expression of cytochrome P450s (CYPs) and UGTs in human hepatocytes were evaluated to assess the potential for drug–drug interactions (DDIs). Mertansine potently inhibited UGT1A1-catalyzed SN-38 glucuronidation, UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-β-glucuronidation, and UGT1A4-catalyzed trifluoperazine N-β-d-glucuronidation, with K(i) values of 13.5 µM, 4.3 µM, and 21.2 µM, respectively, but no inhibition of UGT1A6, UGT1A9, and UGT2B7 enzyme activities was observed in human liver microsomes. A 48 h treatment of mertansine (1.25–2500 nM) in human hepatocytes resulted in the dose-dependent suppression of mRNA levels of CYP1A2, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A9, with IC(50) values of 93.7 ± 109.1, 36.8 ± 18.3, 160.6 ± 167.4, 32.1 ± 14.9, 578.4 ± 452.0, 539.5 ± 233.4, 856.7 ± 781.9, and 54.1 ± 29.1 nM, respectively, and decreased the activities of CYP1A2-mediated phenacetin O-deethylase, CYP2B6-mediated bupropion hydroxylase, and CYP3A4-mediated midazolam 1′-hydroxylase. These in vitro DDI potentials of mertansine with CYP1A2, CYP2B6, CYP2C8/9/19, CYP3A4, UGT1A1, and UGT1A9 substrates suggest that it is necessary to carefully characterize the DDI potentials of ADC candidates with mertansine as a payload in the clinic. MDPI 2020-03-02 /pmc/articles/PMC7150891/ /pubmed/32131538 http://dx.doi.org/10.3390/pharmaceutics12030220 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Won-Gu
Park, Ria
Kim, Dong Kyun
Shin, Yongho
Cho, Yong-Yeon
Lee, Hye Suk
Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
title Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
title_full Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
title_fullStr Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
title_full_unstemmed Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
title_short Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
title_sort mertansine inhibits mrna expression and enzyme activities of cytochrome p450s and uridine 5′-diphospho-glucuronosyltransferases in human hepatocytes and liver microsomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150891/
https://www.ncbi.nlm.nih.gov/pubmed/32131538
http://dx.doi.org/10.3390/pharmaceutics12030220
work_keys_str_mv AT choiwongu mertansineinhibitsmrnaexpressionandenzymeactivitiesofcytochromep450sanduridine5diphosphoglucuronosyltransferasesinhumanhepatocytesandlivermicrosomes
AT parkria mertansineinhibitsmrnaexpressionandenzymeactivitiesofcytochromep450sanduridine5diphosphoglucuronosyltransferasesinhumanhepatocytesandlivermicrosomes
AT kimdongkyun mertansineinhibitsmrnaexpressionandenzymeactivitiesofcytochromep450sanduridine5diphosphoglucuronosyltransferasesinhumanhepatocytesandlivermicrosomes
AT shinyongho mertansineinhibitsmrnaexpressionandenzymeactivitiesofcytochromep450sanduridine5diphosphoglucuronosyltransferasesinhumanhepatocytesandlivermicrosomes
AT choyongyeon mertansineinhibitsmrnaexpressionandenzymeactivitiesofcytochromep450sanduridine5diphosphoglucuronosyltransferasesinhumanhepatocytesandlivermicrosomes
AT leehyesuk mertansineinhibitsmrnaexpressionandenzymeactivitiesofcytochromep450sanduridine5diphosphoglucuronosyltransferasesinhumanhepatocytesandlivermicrosomes